A RECOMBINANT SINGLE CHAIN ANTIBODY INTERLEUKIN-2 FUSION PROTEIN

被引：37

作者：

SAVAGE, P ^{[1
]}

SO, A ^{[1
]}

SPOONER, RA ^{[1
]}

EPENETOS, AA ^{[1
]}

机构：

[1] HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT RHEUMATOL,LONDON W12 OH,ENGLAND

来源：

BRITISH JOURNAL OF CANCER | 1993年 / 67卷 / 02期

关键词：

D O I：

10.1038/bjc.1993.57

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recombinant interleukin-2 (rIL-2) therapy has been shown to be of value in the treatment of some cases of melanoma and renal cell carinoma. However its use can be limited by severe systemic toxicity. Targeting rIL-2 to the tumour should improve the anti-tumour immune response and decrease the systemic toxicity. With this aim we have employed recombinant DNA techniques to construct a single chain antibody interleukin-2 fusion protein (SCA-IL-2). The protein used in this model system comprises the variable domains of the anti-lysozyme antibody D1.3 fused to human IL-2. It has been expressed by secretion from Escherichia coli and the purified product possesses antigen binding specificity and retains the immunostimulatory activities of rIL-2. This approach can be taken to generate SCA-IL-2 proteins that bind to appropriate cellular antigens. In vivo administration of a tumour binding SCA-IL-2 should result in a localised high concentration of IL-2 in tumour tissues, maximising the anti-tumour immune response, whilst keeping systemic side effects to a minimum.

引用

页码：304 / 310

页数：7

共 27 条

[1]

BETTER M, 1990, ICSU SHORT REP, V10, P105

[2] MAKING ANTIBODY FRAGMENTS USING PHAGE DISPLAY LIBRARIES [J].

CLACKSON, T ;

HOOGENBOOM, HR ;

GRIFFITHS, AD ;

WINTER, G .

NATURE, 1991, 352 (6336) :624-628

[3] INVIVO TUMOR TARGETING OF A RECOMBINANT SINGLE-CHAIN ANTIGEN-BINDING PROTEIN [J].

COLCHER, D ;

BIRD, R ;

ROSELLI, M ;

HARDMAN, KD ;

JOHNSON, S ;

POPE, S ;

DODD, SW ;

PANTOLIANO, MW ;

MILENIC, DE ;

SCHLOM, J .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (14) :1191-1197

[4] INTERLEUKIN-2 PRODUCTION BY TUMOR-CELLS BYPASSES T-HELPER FUNCTION IN THE GENERATION OF AN ANTITUMOR RESPONSE [J].

FEARON, ER ;

PARDOLL, DM ;

ITAYA, T ;

GOLUMBEK, P ;

LEVITSKY, HI ;

SIMONS, JW ;

KARASUYAMA, H ;

VOGELSTEIN, B ;

FROST, P .

CELL, 1990, 60 (03) :397-403

[5]

FELL HP, 1991, J IMMUNOL, V146, P2446

[6] ANTIBODY-TARGETED INTERLEUKIN-2 STIMULATES T-CELL KILLING OF AUTOLOGOUS TUMOR-CELLS [J].

GILLIES, SD ;

REILLY, EB ;

LO, KM ;

REISFELD, RA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (04) :1428-1432

[7]

GILLIS S, 1978, J IMMUNOL, V120, P2027

[8] LONG-TERM CULTURE OF TUMOR-SPECIFIC CYTOTOXIC T-CELLS [J].

GILLIS, S ;

SMITH, KA .

NATURE, 1977, 268 (5616) :154-156

[9] HISTAMINE, LEUKOTRIENE-C4 AND INTERLEUKIN-2 INCREASE ANTIBODY UPTAKE INTO A HUMAN CARCINOMA XENOGRAFT MODEL [J].

HENNIGAN, TW ;

BEGENT, RHJ ;

ALLENMERSH, TG .

BRITISH JOURNAL OF CANCER, 1991, 64 (05) :872-874

[10] PROTEIN ENGINEERING OF ANTIBODY-BINDING SITES - RECOVERY OF SPECIFIC ACTIVITY IN AN ANTI-DIGOXIN SINGLE-CHAIN FV ANALOG PRODUCED IN ESCHERICHIA-COLI [J].

HUSTON, JS ;

LEVINSON, D ;

MUDGETTHUNTER, M ;

TAI, MS ;

NOVOTNY, J ;

MARGOLIES, MN ;

RIDGE, RJ ;

BRUCCOLERI, RE ;

HABER, E ;

CREA, R ;

OPPERMANN, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (16) :5879-5883

← 1 2 3 →